254 related articles for article (PubMed ID: 25098025)
21. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study.
Tarlatzis B; Tavmergen E; Szamatowicz M; Barash A; Amit A; Levitas E; Shoham Z
Hum Reprod; 2006 Jan; 21(1):90-4. PubMed ID: 16172149
[TBL] [Abstract][Full Text] [Related]
22. Use of micro-dose human chorionic gonadotropin (hCG) after clomiphene citrate (CC) to complete folliculogenesis in previous CC-resistant anovulation.
Branigan EF; Estes A
Am J Obstet Gynecol; 2005 Jun; 192(6):1890-4; discussion 1894-6. PubMed ID: 15970844
[TBL] [Abstract][Full Text] [Related]
23. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
25. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
[TBL] [Abstract][Full Text] [Related]
26. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group.
J Clin Endocrinol Metab; 1998 May; 83(5):1507-14. PubMed ID: 9589647
[TBL] [Abstract][Full Text] [Related]
28. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women.
Filicori M; Cognigni GE; Tabarelli C; Pocognoli P; Taraborrelli S; Spettoli D; Ciampaglia W
J Clin Endocrinol Metab; 2002 Mar; 87(3):1156-61. PubMed ID: 11889180
[TBL] [Abstract][Full Text] [Related]
29. Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study.
Ng EY; Yeung WS; Ho PC
Hong Kong Med J; 2000 Dec; 6(4):368-74. PubMed ID: 11177158
[TBL] [Abstract][Full Text] [Related]
30. Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon).
Buckler HM; Robertson WR; Anderson A; Vickers M; Lambert A
Hum Reprod; 1999 Dec; 14(12):2969-73. PubMed ID: 10601080
[TBL] [Abstract][Full Text] [Related]
31. [A randomized, single-blind, parallel-controlled and multicentre study: compare the efficacy and safety of domestic and imported human recombinant FSH in WHO group Ⅱ anovulatory infertility].
Zhou YZ; Shen H; Zuo WL; Xu YH; Deng XH; Chen YL; Gao Y; Wang XX; Xu W; Lai QH; Shi H; Liu W; He Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):258-63. PubMed ID: 27116983
[TBL] [Abstract][Full Text] [Related]
32. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect.
O'Dea L; O'Brien F; Currie K; Hemsey G
Curr Med Res Opin; 2008 Oct; 24(10):2785-93. PubMed ID: 18727841
[TBL] [Abstract][Full Text] [Related]
33. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
34. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?
Caserta D; Lisi F; Marci R; Ciardo F; Fazi A; Lisi R; Moscarini M
Gynecol Endocrinol; 2011 Nov; 27(11):862-6. PubMed ID: 21391759
[TBL] [Abstract][Full Text] [Related]
35. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
[TBL] [Abstract][Full Text] [Related]
36. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
Gómez R; Lima I; Simón C; Pellicer A
Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
[TBL] [Abstract][Full Text] [Related]
37. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
38. Ovulation induction using low-dose step-up rFSH in Vietnamese women with polycystic ovary syndrome.
Lan VT; Norman RJ; Nhu GH; Tuan PH; Tuong HM
Reprod Biomed Online; 2009 Apr; 18(4):516-21. PubMed ID: 19400993
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study.
Bühler KF; Fischer R
Gynecol Endocrinol; 2012 May; 28(5):345-50. PubMed ID: 22115012
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility.
Balen AH; Mulders AG; Fauser BC; Schoot BC; Renier MA; Devroey P; Struijs MJ; Mannaerts BM
J Clin Endocrinol Metab; 2004 Dec; 89(12):6297-304. PubMed ID: 15579793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
